alexa Antimetastatic Mechanisms of Bisdioxopiperazine Compound Study, A Gateway to Success | OMICS International
Journal of Cellular and Molecular Pharmacology
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Antimetastatic Mechanisms of Bisdioxopiperazine Compound Study, A Gateway to Success

Da-Yong Lu1,2*, Jian Ding1, Rui-Ting Chen1, Bin Xu1, Nagendra Sastry Yarla3 and Ting-Ren Lu2

1Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, PR China

2Shanghai University, Shanghai, PR China

3GITAM University, AP, India

*Corresponding Author:
Da-Yong Lu
Shanghai Institute of Materia Medica
Chinese Academy of Sciences, Shanghai 201203
PR China
Tel: +862166163545
Fax: +862166132177
E-mail: [email protected]

Received date: August 15, 2017; Accepted date: August 20, 2017; Published date: August 30, 2017

Citation: Lu DY, Ding J, Chen RT, Xu H, Yarla NS, et al. (2017) Antimetastatic Mechanisms of Bisdioxopiperazine Compound Study, A Gateway to Success. J Cell Mol Pharmacol 1:e101.

Copyright: © 2017 Lu DY, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Cellular and Molecular Pharmacology

Abstract

Neoplasm metastasis is the causality of 90% cancer patient’s mortality. Bisdioxopiperazine compounds (Biz compounds) are a series of synthetic agents that are firstly discovered to exhibit antimetastatic efficacy to animal tumor models. In order to completely overcome neoplasm metastasis in clinics, antimetastatic therapeutic study for Biz compounds is of great clinical significance. This editorial highlights these researches from new perspective.

Keywords

Bisdioxopiperazine compounds; Probimane; Razoxane; MST-16; Antimetastatic drugs; Neoplasm metastasis; Drug combinations, Drug development

Background

Cancer is one of the deadliest diseases that cause the 7-10 millions deaths annually worldwide [1-2]. Neoplasm metastasis is prime factor for patient’s deaths (approximately 90% of cancer mortality). Therapeutic benefits in late-staged or aged cancer patients are especially poor and useless [3-4]. Clinical anticancer drug therapies currently in use are mainly focusing on primary tumor growth rather than specifically targeting pathologic courses of metastases. It nevertheless needs changing mindset into other types of drug targets and personalized cancer therapy in clinics [4-7]. One of them is the revisiting of Biz compound study [8-9].

Inventions of Biz Compounds

Biz compounds are a series of synthetic agents that are firstly discovered to exhibit antimetastatic efficacy to animal tumor model. In order to completely overcome neoplasm metastasis in clinics, antimetastatic therapeutic study for Biz compounds is of great clinical significance. Since Biz compounds are unique agents in their pharmacological mechanisms of action of metastases inhibition and are conservative anticancer and antimetastatic activities between Biz compounds, further medicinal chemistry or pharmacological studies seems indispensable [8-10]. The structural formulae of the major Biz compounds are represented in Figure 1.

cellular-molecular-pharmacology-Structural-formulae

Figure 1: Structural formulae of major bisdioxopiperazine compounds.

Current Discoveries

Biz compounds are the earliest anticancer agents found to especially inhibit spontaneous neoplasm metastases [12-14]. Due to these earliest discoveries on neoplasm metastasis inhibition, Biz compounds are widely noticed for cancer metastasis treatment study. So far, a lot of new anticancer activity and mechanisms of Biz compounds have been found [15-31]. Accordingly, it is proposed that anticancer and antimetastatic mechanisms of Biz compounds can be a medical gateway for completely understanding into neoplasm metastasis pathogenesis and their therapeutics in clinics.

Discussion

The major drawback of Biz compounds is low antimetastatic efficacy in clinical trials. Most of past discoveries are come from experimental data. In addition, the debate of high risk of carcinogenesis from Biz compound treatments is difficult to conclude [32-33]. Since there is no definite pathway of anti-metastatic drug developments, we thus suggest that Biz compounds should be carefully studies for both experimental investigations and clinical applications in cancer treatments. Today, we are in front of widely therapeutic failure in cancer metastasis treatments [4-5]. To change this scenario, new generation of pharmacologic/medical researches for Biz compounds, such as personalized cancer treatments [34] are urgently needed.

Summary

In summary, we address and highlight the different inhibitions against metastases in vivo and molecular mechanisms in vitro of Biz compounds, especially relating to the inhibitions of tumor metastasis including pathways of angiogenesis, topoisomerase II, calmodulin, sialic acid, fibrinogen, cell-movements and so on [12-31]. These kinds of researches might be an avenue for the successes of neoplasm metastasis treatments.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Journals

Article Usage

  • Total views: 105
  • [From(publication date):
    December-2017 - Jun 21, 2018]
  • Breakdown by view type
  • HTML page views : 75
  • PDF downloads : 30
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7